Here is another study of Comparison:IE- Why we are BETTER: as done by IMMC JV guys:
Biotech Holdings Ltd -
Biotech's DIAB II diabetes drug different from TZDs
Biotech Holdings Ltd BIO
Shares issued 37,252,913 1999-10-21 close $1
Friday Oct 22 1999
Mr. Robert Rieveley reports
Robert B. Rieveley, president of Biotech Holdings, responding to investor and shareholder inquiries, has clarified some important differences between Biotech's DIAB II and TZDs such as SmithKline Beecham's Avandia, which yesterday received a negative opinion from the scientific advisory panel for the European Agency for the Evaluation of Medicinal Products.
"While DIAB II is an insulin-sensitizing drug, DIAB II is not chemically related to the TZDs, or thiazolidinediones. DIAB II has a unique mechanism of action. At the same time, the data, most recently including a clinical trial in Brazil, strongly suggest that DIAB II is a very benign drug. DIAB II is very effective in reducing symptoms of type II diabetes but is also very safe."
Mr. Rieveley added, "With the demonstrated lack of the toxicity that characterizes some insulin-sensitizing drugs and with demonstrated efficacy, we believe that DIAB II should become the market leader for insulin-sensitizing drugs wherever it is introduced."
DIAB II works by improving the patient's ability to use both endogenous and injected insulin, the hormone that regulates blood sugar levels. Type II or adult-onset diabetes affects more than 15 million people in the United States, over 20 million in Latin America and over 150 million people worldwide.
WARNING: The company relies upon litigation protection for "forward-looking" statements.
canada-stockwatch.com
brokerrelations.com
From the BR.com website :
Published by Deutsche Margan Grenfell
Projections
Immunis Corp. (IMMC-OTCBB) owns interests and invests in developing health care products that address health problems in both developing countries and industrialized nations. The company's interests may be in the form of strategic partnerships, direct ownership interests in patents or the control of commercial or marketing rights. The company's first acquisition was a 25% interest in the commercial rights to DIAB II (a type II diabetes treatment) territory outside of Oriental Asia.
Product/Services
25% interest in commercial rights to DIAB II for territories outside of Oriental Asia. DIAB II is a potent member of a new class of anti-diabetic agents. Effective in treating Type II diabetes.
1) extremely safe: free of toxicity associated with glitazone-class insulin sensitizers
2) increases patient's metabolic rate: increasing energy and feeling of well-being
3) works mainly on muscle cells, not fat cells: weight reduction instead of weight gain
4) delivered by small easy-to-swallow coated tablets
The Market
The market for DIAB II in Latin America is a sizable and very lucrative market. To calculate the potential for revenues, for each one percent of the diabetic population in Brazil and Argentina using DIAB II (a total of 100,000 1-year prescriptions) DIAB II sales revenues generated would be over $20,000,000 per year. Over 150 million people suffer from diabetes worldwide. Worldwide market for Type II Diabetes treatment exceeds $10 billion annually U.S. market for insulin sensitizers expected to grow by more than 50% per year to $5.1 billion by end of 2003.
Corporate Fundamentals/ News
1) Company has no debt
2) Profit margins as high as 60%
3) License agreement with Biobras of Brazil: 4th largest insulin producer in the world with over 75% of Brazilian market
4) Agreement for distribution in Argentina and Brazil in place, Peru, Ecuador, and Venezuela expected shortly
5) Research report including: DIAB II should have sales of close to $200 million U.S. by year-end 2003. Immunis Corp. would have 25% of profits based on those sales.
Year Ending Revenue Pre-Tax Income
2000 (est.) $10 mm $6 mm
2001 (est.) $30 mm $18 mm
2002 (est.) $55 mm $33 mm
2003 (est.) $85 mm $51 mm
CONTACT US
For additional information contact John King at:
Creative Consultations International
888-353-5210.
email: jking@qnet.com
or
Mr. Roberts
Hawke Group, Inc.
965-564-7114
This release contains forward-looking statements within the meaning of Section 21E of the Securities and Exchange Act of 1934, as amended. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, actual results may differ for reasons that include but are not limited to political and economic conditions in the countries in which the Company does or intends to do business, regulatory action, product pricing and competitive market conditions.
DISCLAIMER: Information displayed by CREATIVE CONSULTATIONS INTERNATIONAL does not constitute on offer to buy or sell securities (stocks). CREATIVE CONSULTATIONS INTERNATIONAL does not recommend that any person(s) or institution(s) make buying or selling decisions due to any material on this site. All visitors to this web-site are strongly urged to consult a qualified financial professional before forming any opinions, making any decisions, or taking any actions in regards to information included on this web-site. CREATIVE CONSULTATIONS INTERNATIONAL accepts no responsibility for any investment decisions and we again strongly urge everyone to consult a financial professional before doing so.
Safe Harbor
Chucka - IMMC has 25% of DiabII. BIOHF doen not own 25% of IMMC, IMMC has 25% of BIOHF- SEC Disclosure applies to me as stated CCI, above.
|
